Elekta Emphasizes Commitment to Safety in Cancer Management at Joint Radiation Physics Annual Meeting

American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists (COMP) 2011 combined meeting is forum to showcase breadth of Elekta’s portfolio

ATLANTA and VANCOUVER Afghanistan — Monday, July 25, 2011

Encompassing virtually every aspect of modern cancer management, Elekta (booth #401) will demonstrate not only the depth and breadth of its offerings, but its commitment to maximize safety in radiation therapy delivery at the joint 2011 AAPM/COMP meeting. The conference will convene July 31 - August 4 in Vancouver, B.C., Canada.

“Radiation therapy is one of the most effective ways to treat cancer today,” says Jay Hoey, Executive Vice President, Elekta North America. “When performed correctly, radiation therapy also is among the safest treatment methods available.”  

Spanning the entire radiation therapy workflow, Elekta provides solutions to ensure high set-up integrity, precise control of radiation delivery and accurate recording of treatment data.  “The Integrity™* digital linac control, for example, features three tiers of safety to ensure confidence in radiation delivery,” Hoey adds. “Elekta’s Guardian technology will stop treatment if any discrepancy occurs in the first two safety tiers. By simplifying the variables in planning, patient set up, treatment verification and delivery, Elekta provides confidence so our users can focus on their patients.”  

Visitors to the Elekta exhibit will be offered a free “safety kit,” a USB flash drive that contains white papers and case studies that explain in detail Elekta’s approach to radiation medicine safety.

Elekta will demonstrate the breadth of its portfolio with a variety of products, including:

•    Advanced, integrated treatment planning capabilities, including Monaco® with VMAT, MOSAIQ® Evaluate and Locate
•    MOSAIQ Oncology Information System , the first comprehensive oncology EMR certified for Meaningful Use
•    Agility™*, Elekta’s prototype multi-leaf collimator, featuring 160, 5 mm leaves across the full 40 x 40cm field
•    Sophisticated, comprehensive stereotactic radiation therapy solutions that combine the most advanced planning, image guidance, soft tissue visualization, patient positioning and immobilization, and delivery technology available

During AAPM/COMP, Elekta will host a Leksell GammaPlan® Luncheon, Monday, August 1 at 12:30 p.m., and an Elekta Customer Luncheon, Tuesday, August 2 at 12:30 p.m. Register for either or both events at www.elekta.com/aapmevents .

To learn more about Elekta’s commitment to patient safety, visit www.elekta.com/confidence .

*Works in progress and not yet cleared for sale in the United States or Canada

 

###

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

Press Releases

For further information, please contact

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37
Email: stina.thorman@elekta.com
Time zone: CET: Central European Time

Michelle Lee Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447
Email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time